Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomics of Type 2 Diabetes Mellitus-Induced Gastroenteropathy in the db/db Mouse Model

ABSTRACT: proteomics of Type 2 Diabetes Mellitus-Induced Gastroenteropathy in the db/db Mouse Model

ORGANISM(S): Mus Musculus

SUBMITTER: Yuxin Zhang

PROVIDER: PXD051386 | iProX | Fri Apr 12 00:00:00 BST 2024

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Type 2 Diabetes mellitus: mRNA and miRNA profiling

Project description:This SuperSeries is composed of the following subset Series: GSE21321: Blood microRNA profiles and upregulation of hsa-miR-144 in males with type 2 diabetes mellitus. GSE26167: MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in Type 2 Diabetes mellitus Refer to individual Series

2010-12-18 | E-GEOD-26168 | biostudies-arrayexpress

Serum microRNA profile of human type 1 diabetes mellitus

Project description:To evaluate whether serum micoRNAs can be biomarkers for diagnosis of type 1 diabetes mellitus, we analyzed the serum microRNA expression profiles in 6 patients with new-onset type 1 diabetes mellitus and 6 age- and gender-matched healthy controls. A difference was observed in 31 miRNAs between the patients and controls (fold change ≥ 2, P < 0.05)

2017-02-09 | GSE94649 | GEO

Glucagon regulates Hepatic Kisspeptin1 to Impair Insulin Secretion in Diabetes Mellitus

Project description:Glucagon and insulin are counter-regulatory pancreatic hormones that precisely control blood glucose homeostasis1. Type 2 diabetes mellitus (T2DM) is characterized by inappropriately elevated blood glucagon2-5 levels as well as insufficient glucose stimulated insulin secretion (GSIS) by pancreatic ß-cells6. Early in the pathogenesis of T2DM, hyperglucagonemia is observable antecedent to ß-cell dysfunction7-9; and in mice, liver-specific activation of glucagon receptor-dependent signaling results in impaired GSIS10. However, the mechanistic relationship between hyperglucagonemia, hepatic glucagon action, and ß-cell dysfunction remains poorly understood. Here we show that glucagon action stimulates hepatic production of the neuropeptide kisspeptin1, which acts in an endocrine manner on ß-cells to suppress GSIS. In vivo glucagon administration acutely stimulates hepatic kisspeptin1 production, and kisspeptin1 is increased in livers from humans with T2DM and from mouse models of diabetes mellitus. Synthetic kisspeptin1 potently suppresses GSIS in vivo and in vitro from normal isolated islets, which express the kisspeptin1 receptor Kiss1R. Administration of a Kiss1R antagonist in diabetic Leprdb/db mice potently augments GSIS and reduces glycemia. Our observations indicate in the pathogenesis of T2DM an endocrine mechanism sequentially linking hyperglucagonemia via hepatic kisspeptin1 production to impaired insulin secretion. In addition, our findings suggest Kiss1R antagonism as a therapeutic avenue to improve ß-cell function in T2DM. Total RNA from L-Δprkar1a KO mice compared to control D-glucose mice

2014-04-01 | E-GEOD-48815 | biostudies-arrayexpress

Mitochondrially targeted tamoxifen alleviates markers of obesity and type 2 diabetes mellitus in mice

Project description:Type 2 diabetes mellitus represents a major health problem with increasing prevalence worldwide. Limited efficacy of current therapies have prompted a search for novel therapeutic options. Here we show that treatment of pre-diabetic mice with mitochondrially targeted tamoxifen, a potential anti-cancer agent with senolytic activity, improves glucose tolerance and reduces body weight with most pronounced reduction of visceral adipose tissue due to reduced food intake, suppressed adipogenesis and elimination of senescent cells. Glucose-lowering effect of mitochondrially targeted tamoxifen is linked to improvement of type 2 diabetes mellitus-related hormones profile and is accompanied by reduced lipid accumulation in liver. Lower senescent cell burden in various tissues, as well as its inhibitory effect on pre-adipocyte differentiation, results in lower level of circulating inflammatory mediators that typically enhance metabolic dysfunction. Targeting senescence with mitochodrially targeted tamoxifen thus represents an approach to the treatment of type 2 diabetes mellitus and its related comorbidities, promising a complex impact on senescence-related pathologies in aging population of patients with type 2 diabetes mellitus with potential translation into the clinic.

2022-05-20 | PXD031710 | Pride

Gene expression of Skeletal muscle in Tacrolimus-Induced Post-transplantation Diabetes Mellitus model

Project description:Post-transplantation diabetes mellitus (PTDM) is a known complication of transplantation which affected the prognosis. Tacrolimus (Tac, or FK506) is a widely used immunosuppressant, has been reported as a risk factor for PTDM and further develops complications in heart and skeletal muscle , while the mechanism is still largely unknown. The gene expression of rat muscles of control group and Tac induced PTDM group were analyzed.

2019-11-20 | GSE140691 | GEO

Type 2 Diabetes mellitus: mRNA and miRNA profiling

Project description:Type 2 Diabetes mellitus: mRNA and miRNA profiling

| PRJNA135245 | ENA

Post-transplant diabetes mellitus after kidney transplantation

Project description:Diabetes mellitus (DM) after transplantation remains a crucial clinical problem in kidney transplantation. To obtain insights into molecular mechanisms underlying the development of post-transplant diabetes mellitus (PTDM) and its early impact on glomerular structures, here we comparatively analyze the proteome of histologically normal appearing glomeruli from patients with PTDM from normoglycemic (NG) transplant recipients, and from recipients with pre-existing type 2 DM (PTDM)

2023-10-24 | PXD042188 | Pride

Glucagon regulates Hepatic Kisspeptin1 to Impair Insulin Secretion in Diabetes Mellitus

2014-04-01 | GSE48815 | GEO

Transcriptional profile of peripheral blood mononuclear cells PBMC from type 1 Diabetes Mellitus Patients

Project description:The oligo microarray were used to determine gene expression profiles of PBMC from type 1 diabetes mellitus (T1DM) patients.

2012-08-24 | E-MEXP-3348 | biostudies-arrayexpress

Transcriptional Profiles of peripheral blood mononuclear cells - PBMC - from Type 2 diabetes mellitus Patients

Project description:The oligo microarrays were used to determine gene expression profiles of PBMC from type 2 diabetes mellitus (T2DM) patients.

2012-06-30 | E-MEXP-3287 | biostudies-arrayexpress